Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/JAC/27.SUPPL_C.29PMID 1830302
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activity of sub-minimal inhibitory concentrations of aspoxicillin in prolonging the postantibiotic effect against Staphylococcus aureus.

  1990cited by this paper
• Effects of supra- and sub-MIC benzylpenicillin concentrations on group A beta-haemolytic streptococci during the postantibiotic phase in vivo.

  1990cited by this paper
• Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models.

  1989cited by this paper
• Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia.

  1988cited by this paper
• In vivo postantibiotic effect in a thigh infection in neutropenic mice.

  1988cited by this paper
• Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

  1988cited by this paper
• Efficacy of different dosing schedules of tobramycin for treating a murine Klebsiella pneumoniae bronchopneumonia.

  1987cited by this paper
• Kinetics of antimicrobial activity.

  1986cited by this paper
• Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics.

  1986cited by this paper
• Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin.

  1983cited by this paper
• Evaluation of methods for producing renal dysfunction in rats.

  1981cited by this paper

• Amikacin-eravacycline combination mediates the synergistic elimination of carbapenem-resistant pathogens via in vitro and in vivo metabolic reprogramming

  2026cites this paper
• Therapeutic application of a jumbo bacteriophage against metallo-β-lactamase producing Pseudomonas aeruginosa clinical isolates

  2025cites this paper
• Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and Pseudomonas aeruginosa

  2025cites this paper
• Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and Pseudomonas aeruginosa: Brief Summary

  2025cites this paper
• Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models

  2024influential citation
• CTC-177, a novel drug–Fc conjugate, shows promise as an immunoprophylactic agent against multidrug-resistant Gram-negative bacterial infections

  2024cites this paper
• Pharmacokinetics and Pharmacodynamics of a Novel Vancomycin Derivative LYSC98 in a Murine Thigh Infection Model Against Staphylococcus aureus

  2023cites this paper
• Inoculum-Based Dosing: A Novel Concept for Combining Time with Concentration-Dependent Antibiotics to Optimize Clinical and Microbiological Outcomes in Severe Gram Negative Sepsis

  2023cites this paper
• Streptothricin F is a bactericidal antibiotic effective against highly drug-resistant gram-negative bacteria that interacts with the 30S subunit of the 70S ribosome

  2023cites this paper
• Why We May Need Higher Doses of Beta-Lactam Antibiotics: Introducing the ‘Maximum Tolerable Dose’

  2022cites this paper
• Assessment of In-Vitro Synergy of Fosfomycin with Meropenem, Amikacin and Tigecycline in Whole Genome Sequenced Extended and Pan Drug Resistant Klebsiella Pneumoniae: Exploring A Colistin Sparing Protocol

  2022cites this paper
• Minocycline intra-bacterial pharmacokinetic hysteresis as a basis for pharmacologic memory and a backbone for once-a-week pan-tuberculosis therapy

  2022cites this paper
• Pharmacokinetics and Pharmacodynamics of Nemonoxacin in a Neutropenic Murine Lung Infection Model Against Streptococcus Pneumoniae

  2021cites this paper
• Pharmacodynamic evaluation of meropenem, cefepime, and aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh infection model.

  2021cites this paper
• Development of Novel Immunoprophylactic Agents against Multidrug-Resistant Gram-Negative Bacterial Infections

  2021cites this paper
• Initial In Vivo Evaluation of a Novel Amikacin-Deoxycholate Hydrophobic Salt Delivers New Insights on Amikacin Partition in Blood and Tissues

  2021cites this paper
• Pharmacokinetics and Pharmacodynamics of Vancomycin derivative LYSC98 in a Murine Thigh Infection Model against Staphylococcus aureus

  2021cites this paper
• The utilization of Blaptica dubia cockroaches as an in vivo model to test antibiotic efficacy

  2021cites this paper
• Profiling the in vitro and in vivo activity of streptothricin-F against carbapenem-resistant Enterobacterales: a historic scaffold with a novel mechanism of action

  2021cites this paper
• Predicting Antimicrobial Activity at the Target Site: Pharmacokinetic/Pharmacodynamic Indices versus Time–Kill Approaches

  2021cites this paper
• Pivotal Role of Translation in Anti‐Infective Development

  2021cites this paper
• In Vivo Pharmacodynamics of β-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing Enterobacter cloacae and Klebsiella pneumoniae in Murine Pneumonia Model

  2021cites this paper
• Optimized Extraction of Amikacin from Murine Whole Blood

  2021cites this paper
• Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis

  2021cites this paper
• Effective antimicrobial combination in vivo treatment predicted with microcalorimetry screening

  2021cites this paper
• Pharmacodynamic Evaluation: Infectious Diseases

  2020cites this paper
• Biodegradable nanoparticle based transdermal patches for gentamicin delivery: Formulation, characterization and pharmacokinetics in rabbits

  2020cites this paper
• In vivo studies on antibiotic combination for the treatment of carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis protocol

  2020cites this paper
• Two distinct amphipathic peptide antibiotics with systemic efficacy

  2020cites this paper
• Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective study.

  2020cites this paper
• Imaging of bioluminescent Klebsiella pneumoniae induced pulmonary infection in an immunosuppressed mouse model

  2020cites this paper
• PK/PD Approaches

  2020cites this paper
• Formulation, Pharmacological Evaluation, and Efficacy Studies of Occidiofungin, a Novel Antifungal

  2020influential citation
• A REVIEW ON AMINOGLYCOSIDE ANTIBIOTICS

  2020cites this paper
• Synthesis and evaluation of new quinazolin-4(3H)-one derivatives as potent antibacterial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.

  2019cites this paper
• In vivo study assessed meropenem and amikacin combination therapy against carbapenem-resistant and carbapenemase-producing Enterobacteriaceae strains.

  2019cites this paper
• Evaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing Klebsiella pneumoniae ST405 strains.

  2019cites this paper
• Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections

  2019cites this paper
• Intravenously delivered aminoglycoside antibiotics, tobramycin and amikacin, are not ototoxic in mice.

  2019cites this paper
• Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections

  2019cites this paper
• In Vivo Efficacy of Novel Monobactam LYS228 in Murine Models of Carbapenemase-Producing Klebsiella pneumoniae Infection

  2019cites this paper
• Mechanism of formation of adsorption complexes amikacin–detonation nanodiamond

  2019cites this paper
• Efficacious Analogs of the Lantibiotic Mutacin 1140 against a Systemic Methicillin-Resistant Staphylococcus aureus Infection

  2018cites this paper
• Technologies for Measuring Pharmacokinetic Profiles.

  2018cites this paper
• Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model

  2018cites this paper
• Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer Patients

  2018cites this paper
• Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling

  2018cites this paper
• Pharmacokinetic and Pharmacodynamics Relationships

  2017cites this paper
• Impact du sepsis et de l'épuration extra-rénale sur la pharmacocinétique des antibiotiques.

  2017cites this paper
• Diphenyleneiodonium chloride (DPIC) displays broad-spectrum bactericidal activity

  2017cites this paper
• In vitro Pharmacokinetics/Pharmacodynamics Evaluation of Fosfomycin Combined with Amikacin or Colistin against KPC2-Producing Klebsiella pneumoniae

  2017cites this paper
• Repurposing Ivacaftor for treatment of Staphylococcus aureus infections.

  2017cites this paper
• Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial.

  2017cites this paper
• Translational PK/PD of anti-infective therapeutics.

  2016cites this paper
• Aminoglycosides: An Overview.

  2016cites this paper
• Animal Models to Evaluate Anti-infective Pharmacodynamics

  2016cites this paper
• RESPIRATORY TRACT INFECTIONS : DIRECTIONS FOR THE ' 90 s Once-daily dosing of aminoglycosides

  2016cites this paper
• Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease

  2016cites this paper
• Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents.

  2016cites this paper
• Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy

  2016cites this paper
• Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis

  2016cites this paper
• Plazomicin is effective in a non-human primate pneumonic plague model.

  2016cites this paper
• Optimizing beta-lactam antibiotic dosing in critically ill patients: Prolonged infusion versus intermittent bolus administration

  2016cites this paper
• Dose Timing of Aminoglycosides in Hemodialysis Patients: A Pharmacology View

  2016cites this paper
• Extended-Interval Aminoglycoside Use in Cystic Fibrosis Exacerbation in Children and Young Adults

  2016cites this paper
• Are new gentamicin dosing guidelines suitable for achieving target concentrations in patients with sepsis and septic shock?

  2016cites this paper
• Antimicrobial Pharmacokinetics and Pharmacodynamics

  2015cites this paper
• How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?

  2015cites this paper
• Integrated in vitro and in silico studies for optimisation of broad-spectrum antibiotic combination therapy

  2015cites this paper
• Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model

  2015cites this paper
• Efficacy of Zincoderm G Cream Against Wound Infection by Pseudomonas Aeruginosa in Sprague-Dawley Rats

  2015cites this paper
• Efficiency of gentamicin loaded in bacterial polysaccharides microcapsules against intracellular Gram-positive and Gram-negative invasive pathogens

  2015cites this paper
• Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model

  2015cites this paper
• The Routes of Administration of Amikacin as Consideration in Reptile Therapy

  2015cites this paper
• Efficiency of gentamicin loaded in bacterial polysaccharides microcapsules against intracellular Gram-positive and Gram-negative invasive pathogens.

  2015cites this paper
• Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development

  2015cites this paper
• Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics

  2014cites this paper
• Principles of Applied Pharmacokinetic–Pharmacodynamic Modeling

  2014cites this paper
• Aerosol Phage Therapy Efficacy in Burkholderia cepacia Complex Respiratory Infections

  2014cites this paper
• Strategies for optimization of Aminoglycoside and Vancomycin therapies : a Pharmacokinetic approach

  2014cites this paper
• Profil Farmakokinetik Amikasin Pemberian Intravena Melalui Vena Sublingualis dan Coccygea pada Ular Sanca Batik (PHARMACOKINETIC PROFILE OF AMIKACIN ADMINISTERED INTRA VENOUSLY VIA SUBLINGUAL AND COCCYGEA VEINS IN BROGHAMMERUS RETICULATUS)

  2014cites this paper
• Broad-spectrum β-lactams in obese non-critically ill patients

  2014cites this paper
• Introduction to Pharmacodynamics

  2014cites this paper
• Broad-spectrum b-lactams in obese non-critically ill patients

  2014cites this paper
• Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis

  2014cites this paper
• Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity.

  2014cites this paper
• Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs

  2013influential citation
• model.in a newly developed in vitro kinetic benzylpenicillin against Streptococcus Pharmacodynamic effects of sub-MICs of

  2013cites this paper
• Antimicrobial Treatment of Febrile Neutropenia: Pharmacokinetic–Pharmacodynamic Considerations

  2013cites this paper
• Aminoglycoside ( AG ) antimicrobial agents are potent therapeutics against a wide variety of gram positive and negative bacteria

  2013cites this paper
• PK/PD models in antibacterial development.

  2013cites this paper
• Bioluminescence and 19F Magnetic Resonance Imaging Visualize the Efficacy of Lysostaphin Alone and in Combination with Oxacillin against Staphylococcus aureus in Murine Thigh and Catheter-Associated Infection Models

  2013cites this paper
• 19F Magnetic Resonance Imaging of Perfluorocarbons for the Evaluation of Response to Antibiotic Therapy in a Staphylococcus aureus Infection Model

  2013cites this paper
• AMPHIPHILIC POLYGAMMA GLUTAMIC ACID DERIVATIVES FOR THE DELIVERY OF AMIKACIN TO THE LUNG

  2013cites this paper
• Case-Control Study of Drug Monitoring of (cid:1) -Lactams in Obese Critically Ill Patients

  2013cites this paper
• Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.

  2013cites this paper
• Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis

  2013cites this paper
• Pharmacokinetics of Tulathromycin in Healthy and Neutropenic Mice Challenged Intranasally with Lipopolysaccharide from Escherichia coli

  2012cites this paper
• Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs.

  2012cites this paper
• Case-Control Study of Drug Monitoring of β-Lactams in Obese Critically Ill Patients

  2012cites this paper